Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 4/20 | 0.43 |
| ▸ | VDR | P11473 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.31 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.31 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.31 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.31 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.31 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.31 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.31 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.31 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655523 | 1.00 | GCGR (0.43) | GCGRVDRACKR3MAPTL3MBTL1 | |
| SCHEMBL2660618 | 0.93 | GCGR (0.39) | GCGRVDRMAPTSMN1; SMN2MCL1 | |
| SCHEMBL2653659 | 0.93 | GCGR (0.39) | GCGRVDRMAPTSMN1; SMN2MCL1 | |
| SCHEMBL2652220 | 0.92 | GCGR (0.51) | GCGRVDRACKR3ADCY6ADCY3 | |
| SCHEMBL2655387 | 0.92 | GCGR (0.51) | GCGRVDRACKR3ADCY6ADCY3 | |
| SCHEMBL12064613 | 0.88 | MAPT (0.35) | GCGRMAPTSMN1; SMN2LMNA | |
| SCHEMBL2653808 | 0.86 | GCGR (0.51) | GCGRVDRACKR3MAPTSMN1; SMN2 | |
| SCHEMBL2658848 | 0.85 | GCGR (0.46) | GCGRMCL1PPARGPPARDPPARA | |
| SCHEMBL2658849 | 0.85 | GCGR (0.46) | GCGRMCL1PPARGPPARDPPARA | |
| SCHEMBL2654237 | 0.84 | GCGR (0.49) | GCGRVDRACKR3MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084489-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084489-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100137417-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2010-06-03 | — | — | US | disclosed |
| US-20100137417-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2010-06-03 | — | — | US | disclosed |
| EP-1856090-B1 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2009-10-14 | — | — | EP | disclosed |
| EP-1856090-B1 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2009-10-14 | — | — | EP | disclosed |
| EP-1856090-A2 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006086488-A2 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006086488-A2 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137417-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | GCGR 2/4885VDR 559/4885ACKR3 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.